Scientific Industries Reports Strong Q3 Financial Performance
Three Consecutive Quarters of Revenue Growth in Bioprocessing Operations
Operational Efficiencies Result in Reduced Net Losses by 46% and 34%
Preparation for Two Major New Product Launches in Early 2025
Investor Call Scheduled for November 15 at 11:00 a.m. Eastern Time
BOHEMIA, N.Y. — Scientific Industries, Inc. (OTCQB: SCND), a leading provider of life sciences tools and innovator in digitally simplified bioprocessing technology, has reported robust financial results for the three- and nine-month periods concluding on September 30, 2024. This impressive performance reflects the company's commitment to growth and innovation.
Business Highlights of Q3 2024
Key Developments:
- The validation of the Company’s DOTS MPS system in the mammalian cell culture market opens doors to a vast addressable audience.
- Reception of the new VIVID WORKSTATION aimed at pharmacy chain stores during major trade shows has been exceptionally positive.
- The company’s focus on optimizing working capital has led to a continuous decline in operating expenses and improved cash conservation over the past four quarters.
- Operating cash outflow for the nine-month period significantly shrank to $3.3 million from $4.8 million year-over-year.
Financial Highlights
The Company's net revenues for the third quarter totaled $2.8 million, reflecting a 7.1% increase compared to the same period last year, while revenues for the nine-month period amounted to $7.9 million, showing a decrease of 5.7%. Below are further insights:
- Benchtop Laboratory Equipment Operations achieved net sales of $2.3 million, marking a 7.1% increase, while the nine-month sales reached $6.8 million, a decrease of 8.0% compared to prior year.
- Sales in Bioprocessing Systems Operations were notably strong, reaching $0.45 million in the third quarter, an upturn of 6.6%. For the nine-month period, sales were $1.1 million, reflecting an increase of 11.6%.
- Gross profit was recorded at $1.4 million for the third quarter, an increase of 15.4%. For the nine-month period, the gross profit was $3.7 million, a decrease of 4.4% from the prior year.
- Noteworthy gross margins improved by 350 basis points, achieving 49.2% for the third quarter and 46.8% for the nine-month period.
- The Company bolstered its working capital to $8 million as of September 30, 2024, a marked increase from $6.4 million from the previous year.
Management Insights on Business Performance
Chairman John Moore expressed optimism about the Company's achievements: “This third quarter stands out as the most successful in our history. The rapid market adoption of the DOTS MPS system reinforces our belief in its market potential. With substantial traction in mammalian cell culture, we are confident in accelerating growth in our $4.4 million DOTS pipeline beginning in early 2025.”
Chief Executive Officer Helena Santos added, “I am proud of the strides we’ve made this quarter. A 7% top-line growth and improved gross margins are testaments to our operational efficiencies. These enhancements position us well for the future as we unveil new products and expand into underrepresented markets, ensuring sustainable growth for our stakeholders.”
Looking Ahead: Q4 and Beyond
As the Company anticipates the final quarter of its fiscal year, it remains optimistic about the favorable market trends in demand for its legacy Genie brand products. The impending launch of the state-of-the-art VIVID WORKSTATION further enhances its automated pill counting offerings, providing significant opportunities to improve pharmacy efficiency.
With a keen focus on financial management, Scientific Industries, Inc. (OTCQB: SCND) is poised to unlock distinct long-term shareholder value.
Frequently Asked Questions
What were the main highlights of Scientific Industries' Q3 2024 results?
Scientific Industries reported a 7.1% increase in net revenues and operational efficiencies that significantly reduced net losses compared to previous periods.
How did the new products perform in the market?
The new VIVID WORKSTATION received positive feedback at major trade shows, indicating strong market interest.
What impact did the DOTS MPS system have on the company?
Since its launch, the DOTS MPS system has become the best-selling product for Scientific Industries, indicating strong demand and market validation.
What are the expectations for future growth?
The company aims to accelerate growth by expanding into the mammalian cell culture segment, which presents a significant long-term opportunity.
When is the next investor call scheduled?
The investor call is set for November 15, 2024, at 11:00 a.m. Eastern Time, where further company insights will be shared.
